‘Worried to death’: the assessment and management of anxiety in patients with advanced life-limiting disease, a national survey of palliative medicine physicians

Abstract

BackgroundAnxiety adversely affects quality of life and is common in adults with advanced life-limiting disease. There are no UK-wide guidelines on the assessment and management of anxiety in this specific population and there is little evidence regarding drug treatments. This study aimed to explore how palliative care physicians assess and manage anxiety in their patients, and to identify barriers encountered.MethodsA cross-sectional survey was undertaken of all physicians working in specialist palliative care in the UK who were members of the Association for Palliative Medicine. This was conducted in February 2014 using an online questionnaire.ResultsThe response rate was 23% (230/980) and 61% of respondents were consultants. Most did not use tools to screen for anxiety (87%) and almost all used the clinical interview to diagnose anxiety (99%). Only 8% used psychiatric criteria. Most physicians reported difficulties managing anxiety (93%). Only 33% thought they had adequate training in this area. Most had difficulty accessing psychological and/or psychiatric services (71%, 64% respectively). The majority used a combination of pharmacological and non-pharmacological treatments for anxiety. The most frequently prescribed first-line medications for patients with a prognosis of days to weeks were benzodiazepines (93%), usually lorazepam. The use of benzodiazepines over antidepressants was statistically significant (p < 0.001). For patients with a prognosis of months, antidepressants were most frequently prescribed first-line (60%), significantly more than benzodiazepines (p < 0.001). However, benzodiazepine use was still common in this prognostic group with 47% prescribing it first-line, sometimes in combination with an antidepressant.ConclusionThis is the first national survey on the assessment and management of anxiety in palliative care. Findings demonstrate the infrequent use of screening tools, variation in prescribing practice, potentially inappropriate use of benzodiazepines for patients with a prognosis of months, training gaps and poor access to psychological and psychiatric services in the UK. This highlights the need for formal training, further research into the pharmacological management of anxiety in this population and evidence-based national guidance to support clinical decision-making and service development.

Expressive writing as a therapeutic intervention for people with advanced disease: a systematic review

“…This is perhaps reflected in varied, scant provision and limited practice guidelines [10]. Palliative care clinicians also report that they have limited access to referring patients to psychological services [11]. Moreover, with increasing pressure on service funding, there is an even greater need for evidence of intervention benefit [12].…”

Access to and adequacy of psychological services for adult patients in UK hospices: a national, cross-sectional survey

“…Despite this, 41% reported problems accessing services provided by local mental health trusts. Another more recent survey of palliative care physicians working in hospice and hospital settings in the UK found provision of psychological support remained limited, with the majority of respondents (64%) reporting difficulty accessing psychological services [14]. This survey highlighted lack of formal referral systems as one of the main challenges to accessing these services.…”

Clinical Care Conditions and Needs of Palliative Care Patients from Five Italian Regions: Preliminary Data of the DEMETRA Project

“…Patients with cancer seem to be more vulnerable mentally, and, as observed in other studies [18,[22][23][24], mental health issues such as anxiety and depressive symptoms are very frequent. As reported in dedicated studies [25], this makes it particularly important for palliative care paths to collect information on the psychological state of patients and caregivers so that adequate access to psychological and psychiatric services can be provided. The ESAS has been demonstrated to effectively assess the distressing symptoms impairing patients' quality of life and can be utilized to evaluate the symptom status at baseline as well as the impact of symptom management strategies on the overall disease burden [26].…”